cTfRmAb-EPO

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NamecTfRmAb-EPO

Drug Alias Namebispecific erythropoietin-transferrin receptor antibody fusion protein (ArmaGen Technologies)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionTransferrin receptors modulatorsErythropoietin receptor agonists

TargetsTransferrin receptorsErythropoietin receptor

Therapy Area/IndicationsAmnesia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesArmagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesArmagen Inc

Active IndicationsN/A

Inactive IndicationsAmnesia

Other Information

ATC CodeN/A